AAAAAA

   
Results: 1-16 |
Results: 16
Phase II evaluation of suramin in advanced renal cell carcinoma - A Southwest Oncology Group study
Authors: Schroder, LE Lew, D Flanigan, RC Eisenberger, MA Seay, TE Hammond, N Needles, BM Crawford, ED
Citation: Le. Schroder et al., Phase II evaluation of suramin in advanced renal cell carcinoma - A Southwest Oncology Group study, UROL ONCOL, 6(4), 2001, pp. 145-148
Bacillus Calmette-Guerin: Is monthly maintenance an option for transitional cell carcinoma of the bladder?
Authors: Flanigan, RC DeLaurentis, DA Waters, WB Kunz, K
Citation: Rc. Flanigan et al., Bacillus Calmette-Guerin: Is monthly maintenance an option for transitional cell carcinoma of the bladder?, UROL ONCOL, 6(1), 2001, pp. 16-19
Alterations in peripheral B cells and B cell progenitors following androgen ablation in mice
Authors: Ellis, TM Moser, MT Le, PT Flanigan, RC Kwon, ED
Citation: Tm. Ellis et al., Alterations in peripheral B cells and B cell progenitors following androgen ablation in mice, INT IMMUNOL, 13(4), 2001, pp. 553-558
Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer
Authors: Flanigan, RC Salmon, SE Blumenstein, BA Bearman, SI Roy, V McGrath, PC Caton, JR Munshi, N Crawford, ED
Citation: Rc. Flanigan et al., Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer, N ENG J MED, 345(23), 2001, pp. 1655-1659
T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer
Authors: Mercader, M Bodner, BK Moser, MT Kwon, PS Park, ESY Manecke, RG Ellis, TM Wojcik, EM Yang, D Flanigan, RC Waters, WB Kast, WM Kwon, ED
Citation: M. Mercader et al., T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer, P NAS US, 98(25), 2001, pp. 14565-14570
Assessing the effect of fatty acids on prostate carcinogenesis in humans: does self-reported dietary intake rank prostatic exposure correctly?
Authors: Freeman, VL Meydani, M Yong, S Pyle, J Durazo-Arvizu, R Liao, YL Flanigan, RC Waters, WB
Citation: Vl. Freeman et al., Assessing the effect of fatty acids on prostate carcinogenesis in humans: does self-reported dietary intake rank prostatic exposure correctly?, AM J CLIN N, 73(4), 2001, pp. 815-820
Comparative analysis of DNA flow cytometry and cytology of bladder washings: Review of discordant cases
Authors: Bakhos, R Shankey, TV Flanigan, RC Fisher, S Wojcik, EM
Citation: R. Bakhos et al., Comparative analysis of DNA flow cytometry and cytology of bladder washings: Review of discordant cases, DIAGN CYTOP, 22(2), 2000, pp. 65-69
Renal cell carcinoma with metastasis to the thyroid gland
Authors: Pitale, SU Sizemore, GW Bakhos, R DeJong, SA Flanigan, RC Emanuele, NV
Citation: Su. Pitale et al., Renal cell carcinoma with metastasis to the thyroid gland, UROL ONCOL, 5(4), 2000, pp. 173-175
Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging
Authors: Catalona, WJ Southwick, PC Slawin, KM Partin, AW Brawer, MK Flanigan, RC Patel, A Richie, JP Walsh, PC Scardino, PT Lange, PH Gasior, GH Loveland, KG Bray, KR
Citation: Wj. Catalona et al., Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging, UROLOGY, 56(2), 2000, pp. 255-260
Percentage of free PSA in black versus white men for detection and stagingof prostate cancer: A prospective multicenter clinical trial
Authors: Catalona, WJ Partin, AW Slawin, KM Naughton, CK Brawer, MK Flanigan, RC Richie, JP Patel, A Walsh, PC Scardino, PT Lange, PH deKernion, JB Southwick, PC Loveland, KG Parson, RE Gasior, GH
Citation: Wj. Catalona et al., Percentage of free PSA in black versus white men for detection and stagingof prostate cancer: A prospective multicenter clinical trial, UROLOGY, 55(3), 2000, pp. 372-376
The extent of biopsy involvement as an independent predictor of extraprostatic extension and surgical margin status in low risk prostate cancer: Implications for treatment selection
Authors: Gao, X Mohideen, N Flanigan, RC Waters, WB Wojcik, EM Leman, CR
Citation: X. Gao et al., The extent of biopsy involvement as an independent predictor of extraprostatic extension and surgical margin status in low risk prostate cancer: Implications for treatment selection, J UROL, 164(6), 2000, pp. 1982-1986
Prostatic levels of fatty acids and the histopathology of localized prostate cancer
Authors: Freeman, VL Meydani, M Yong, S Pyle, J Flanigan, RC Waters, WB Wojcik, EM
Citation: Vl. Freeman et al., Prostatic levels of fatty acids and the histopathology of localized prostate cancer, J UROL, 164(6), 2000, pp. 2168-2172
Infusional interleukin-2 and 5-fluorouracil with subcutaneous interferon-alpha for the treatment of patients with advanced renal cell carcinoma - A southwest oncology group phase II study
Authors: Elias, L Lew, D Figlin, RA Flanigan, RC Thompson, ME Triozzi, PL Belt, RJ Wood, DP Rivkin, SE Crawford, ED
Citation: L. Elias et al., Infusional interleukin-2 and 5-fluorouracil with subcutaneous interferon-alpha for the treatment of patients with advanced renal cell carcinoma - A southwest oncology group phase II study, CANCER, 89(3), 2000, pp. 597-603
Daily subcutaneous ultra-low-dose interleukin 2 with daily low-dose interferon-alpha in patients with advanced renal cell carcinoma
Authors: Clark, JI Gaynor, ER Martone, B Budds, SC Manjunath, R Flanigan, RC Waters, WB Sosman, JA
Citation: Ji. Clark et al., Daily subcutaneous ultra-low-dose interleukin 2 with daily low-dose interferon-alpha in patients with advanced renal cell carcinoma, CLIN CANC R, 5(9), 1999, pp. 2374-2380
Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: A prospective multicenter clinical trial
Authors: Southwick, PC Catalona, WJ Partin, AW Slawin, KM Brawer, MK Flanigan, RC Patel, A Richie, JP Walsh, PC Scardino, PT Lange, PH Gasior, GH Parson, RE Loveland, KG
Citation: Pc. Southwick et al., Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: A prospective multicenter clinical trial, J UROL, 162(4), 1999, pp. 1346-1351
5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: A Department of Veterans Affairs Cooperative Study - Reply
Authors: Flanigan, RC Reda, DJ Wasson, JH Anderson, RJ Abdellatif, M Bruskewitz, RC
Citation: Rc. Flanigan et al., 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: A Department of Veterans Affairs Cooperative Study - Reply, J UROL, 161(2), 1999, pp. 614-614
Risultati: 1-16 |